See more : Nevada Canyon Gold Corp. (NGLD) Income Statement Analysis – Financial Results
Complete financial analysis of Purple Biotech Ltd. (PPBT.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Purple Biotech Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- ICL Group Ltd (ICL.TA) Income Statement Analysis – Financial Results
- CarTrade Tech Limited (CARTRADE.NS) Income Statement Analysis – Financial Results
- Arisawa Mfg. Co., Ltd. (5208.T) Income Statement Analysis – Financial Results
- California Resources Corporation (CRCQW) Income Statement Analysis – Financial Results
- Abirami Financial Services (India) Limited (ABIRAFN.BO) Income Statement Analysis – Financial Results
Purple Biotech Ltd. (PPBT.TA)
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.80K | 0.00 | 0.00 | 1.00M | 1.00M | 1.00M | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 196.00K | 120.00 | 55.00 | 58.00 | 80.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -196.00 | -120.00 | -55.00 | 999.94K | 999.92K | 1.00M | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -0.10% | 0.00% | 0.00% | 99.99% | 99.99% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.03M | 16.32M | 11.83M | 7.49M | 2.67M | 5.27M | 4.64M | 4.18M | 2.56M | 3.19M | 109.00K |
| General & Administrative | 0.00 | 5.96M | 5.82M | 6.07M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M |
| Selling & Marketing | 0.00 | 321.00K | 286.00K | 235.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.04M | 6.28M | 6.11M | 6.31M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M |
| Other Expenses | -44.54M | 0.00 | 0.00 | -15.66M | -216.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -22.47M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M |
| Cost & Expenses | -22.27M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M |
| Interest Income | 474.00 | 969.00K | 320.00K | 254.00K | 151.00K | 93.00K | 106.00K | 138.00K | 94.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 126.00K | 212.00K | 61.00K | 181.00K | 576.00K | 26.00K | 6.00K | 3.00K | 21.00K | 48.00K |
| Depreciation & Amortization | 46.00K | 49.00K | 231.00K | 235.00K | 179.00K | 7.00K | 4.00K | 2.00K | 1.00K | -50.00K | 1.36M |
| EBITDA | -22.23M | -21.43M | -17.38M | -28.41M | -7.64M | -7.73M | -11.93M | -7.04M | -4.20M | -5.23M | -1.20M |
| EBITDA Ratio | -11,350.64% | 0.00% | 0.00% | -2,796.00% | -763.80% | -772.60% | -11,929.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | -7.83M | -11.93M | -7.18M | -4.07M | -5.18M | -2.55M |
| Operating Income Ratio | 11,374.13% | 0.00% | 0.00% | 1,261.20% | -715.60% | -782.60% | -11,933.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -42.25M | 843.00K | 108.00K | -15.46M | 1.96M | 2.26M | -1.04M | -4.94M | -133.00K | -71.00K | -75.00K |
| Income Before Tax | -19.98M | -21.76M | -17.83M | -28.07M | -5.89M | -5.57M | -13.01M | -12.13M | -4.20M | -5.25M | -2.63M |
| Income Before Tax Ratio | -10,202.55% | 0.00% | 0.00% | -2,807.40% | -589.30% | -556.90% | -13,008.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 877.00K | 637.00K | -15.67M | 216.00K | 207.00K | -710.00K | 6.00K | -76.00K | 0.00 | -1.31M |
| Net Income | -19.88K | -21.67M | -18.38M | -28.00M | -5.85M | -5.20M | -12.27M | -12.13M | -4.20M | -5.25M | -2.63M |
| Net Income Ratio | -10.15% | 0.00% | 0.00% | -2,799.90% | -585.00% | -520.00% | -12,272.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -0.12 | -0.10 | -0.24 | -0.30 | -0.37 | -1.30 | -2.11 | -4.37 | -23.45 | -32.05 |
| EPS Diluted | -0.09 | -0.12 | -0.10 | -0.24 | -0.30 | -0.37 | -1.30 | -2.11 | -4.37 | -23.44 | -32.03 |
| Weighted Avg Shares Out | 221.33M | 180.81M | 175.68M | 115.00M | 19.37M | 14.21M | 9.46M | 5.76M | 962.00K | 224.00K | 82.00K |
| Weighted Avg Shares Out (Dil) | 221.33M | 180.81M | 175.68M | 115.00M | 19.37M | 14.21M | 9.46M | 5.76M | 962.52K | 224.08K | 82.06K |
Source: https://incomestatements.info
Category: Stock Reports